Millions of people with HIV/AIDS worldwide are living with serious concurrent infections, including chronic viral hepatitis B (HBV) and hepatitis C (HCV), both of which are particularly prevalent in Asia. Most global health experts agree that in conjunction with universal access to ARV therapy, diagnosis and treatment of HIV co-infections must become a priority in resource-limited settings. Despite many challenges, encouraging progress continues in the development of screening tools and effective drug therapies for viral hepatitis co-infections, and in making them widely available to people in need.
Discussion focused on major scientific advances in screening and therapeutics, as well as approaches to overcoming barriers to access. Participants shared scientific and programmatic expertise, debated critical issues and identified practical ways to rapidly expand access to screening and treatment in heavily impacted communities.
The report of the meeting will distil this information and provide a roadmap for further international and local action to aggressively take advantage of the new breakthroughs in diagnosis and treatment.
Reports
The full conference report will be available soon.
Related events
Scaling up HIV/AIDS treatment as prevention
The new era in HIV/AIDS treatment and prevention: science, implementation and finance
